Skip to main content
Premium Trial:

Request an Annual Quote

Saga Diagnostics, AstraZeneca Ink Digital PCR Assay Development Deal

NEW YORK – Saga Diagnostics said Tuesday that it has entered into an assay development agreement with AstraZeneca, under which it will develop digital PCR assays for undisclosed methylated targets in both tissue and liquid biopsies. 

James Hadfield, AstraZeneca's director of epigenomics, oncology translational medicine, and oncology R&D, said in a statement that the choice to work with Lund, Sweden-based Saga reflects the "ultrasensitive performance" of its SagaSafe technology, and its ability to tailor complex, custom assays. 

SagaSafe, formerly IBSafe, is a patented digital PCR method that the company says improves sensitivity up to 100-fold over competitors. 

Financial terms of the deal were not disclosed. 

In addition to its new partnership with AstraZeneca Saga has an ongoing collaboration with University College London, in which it is using SagaSafe to detect EGFR and other gene mutations in clinical tissue samples from the Cancer Research UK-funded, UCL-sponsored TRACERx and PEACE studies. 

The firm also recently raised $12.5 million in a Series A financing round.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.